Back

Cholesterol efflux capacity and subclinical atherosclerosis: is its impact greater in early stages?

1 September 2025 (14:50 - 15:00)
Organised by: Logo
Congress Presentation Part of: Novel biomarkers for cardiovascular risk assessment Biomarkers ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Doctor Warren Skoza

Spanish National Centre for Cardiovascular Research, Madrid (Spain)

3 More presentations in this session

Presentation thumbnail
Incident CHD, residual risk and traditional cardiovascular risk factors in the community: role of lipid-inflammatory axis
Doctor N. Arnold (Hamburg, DE)
Abstract Slides
Presentation thumbnail
Association between genetic polymorphisms in multiple thrombosis-related genes and long-term prognosis in coronary artery disease patients: a large-scale cohort study
Miss K. Zhang (Beijing, CN)
Abstract Slides
Presentation thumbnail
Prognostic value of GDF-15 in patients with suspected myocardial infarction
Doctor J. Lehmacher (Hamburg, DE)
Abstract Slides

Access the full session

Session thumbnail
Novel biomarkers for cardiovascular risk assessment
Video

The Event

Event poster

ESC Congress 2025

1 September 2025 14:50 CET
You may be interested in
thumbnail
Congress Presentation
Remnant cholesterol and its role in patients with coronary atherosclerosis evaluated by coronary CT
thumbnail
Congress Presentation
Impaired high-density lipoprotein-associated cholesterol efflux capacity predicts coronary rapid plaque progression
thumbnail
Congress Presentation
Lipoprotein(a) levels and cholesterol efflux capacity: inverse association and impact on atherosclerosis in familial hypercholesterolemia patients on lipid-lowering therapy

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources